Dermata Therapeutics, Inc. 8-K

What Happened
Dermata Therapeutics, Inc. (DRMA) announced and furnished a press release on May 13, 2026 reporting its results of operations for the quarter ended March 31, 2026 and providing a corporate update. The disclosure was made in a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release dated May 13, 2026 titled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026.”
• Financial results disclosed relate to the quarter ended March 31, 2026.
• The press release was furnished as Exhibit 99.1 to the Form 8-K; the filing also includes the Inline XBRL cover page (Exhibit 104).
• The 8-K reporting these items was filed on May 13, 2026.

Why It Matters
This filing is the company’s formal public disclosure of its quarterly operating results and related corporate developments. For investors, the press release will contain the specific financial figures, operational highlights, and management commentary needed to assess Dermata’s recent performance and near-term outlook. Retail investors should read the attached press release (Exhibit 99.1) and monitor any follow-up filings or investor materials for details on revenue, expenses, cash position, guidance, and strategic initiatives.